Korean Journal of Schizophrenia Research (대한조현병학회지)

Korean Society for Schizophrenia Research (대한조현병학회)
권호 표지
DOI QR코드

DOI QR Code

Association of the First Antipsychotic Treatment Duration With the Re-Initiation of Treatment in Schizophrenia: A National Health Insurance Data-Based Study

  • Song, Minho (Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Jungsun (Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Harin (Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Ahn, Soojin (Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Choi, Young Jae (Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jo, Young Tak (Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Joo, Sung Woo (Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2021.08.22
  • Accepted : 2021.09.29
  • Published : 2021.10.30
⟨ Previous Next ⟩

Abstract

Objectives: The optimal duration of maintenance treatment for patients with first-episode schizophrenia (FES) remains unclear. We examined the first antipsychotic treatment duration and its association with re-initiation of treatment using a nationwide claim database. Methods: Data from the Health Insurance Review and Assessment Service database in South Korea for 2007-2016 were used. Linear regression analysis and Cox proportional hazard models were used to evaluate the associations between the duration of the first antipsychotic treatment, time to re-initiation of treatment, and occurrence of treatment re-initiation. Results: Of 30,143 patients with FES, 80.4% (n=24,231) received <2 years of the first antipsychotic treatment. In patients who discontinued treatment (n=23,030), the rate of treatment re-initiation was 74.2% (n=17,086). As the duration of the first antipsychotic treatment increased, the time to re-initiation of treatment decreased (β=-0.146, p<0.001); however, the rate of treatment reinitiation was relatively constant (hazard ratio=1.001, p<0.001). Conclusion: Long-term antipsychotic treatment was not significantly associated with the rate of treatment re-initiation but showed a negative association with the time to re-initiation of treatment. Further research is needed to better understand the optimal treatment duration for FES.

Keywords

References

  1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67-76. https://doi.org/10.1093/epirev/mxn001
  2. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247. https://doi.org/10.1001/archpsyc.56.3.241
  3. Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001;158:1835-1842. https://doi.org/10.1176/appi.ajp.158.11.1835
  4. Boonstra G, Burger H, Grobbee DE, Kahn RS. Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. Int J Psychiatry Clin Pract 2011;15:128-134. https://doi.org/10.3109/13651501.2010.534801
  5. Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, von Wilmsdorff M, et al. Relapse prevention in first-episode schizophrenia: maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2011;72:205-218. https://doi.org/10.4088/JCP.09m05459yel
  6. Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez G. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry 2012;73:e541-547. https://doi.org/10.4088/JCP.11m07138
  7. McCreadie RG, Wiles D, Grant S, Crockett GT, Mahmood Z, Livingston MG, et al. The Scottish first episode schizophrenia study: VII. two-year follow-up. Acta Psychiatr Scand 1989;80:597-602. https://doi.org/10.1111/j.1600-0447.1989.tb03032.x
  8. Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry 2007;68 Suppl 14:27-30.
  9. Wyatt RJ. Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull 1997;23:3-9. https://doi.org/10.1093/schbul/23.1.3
  10. Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996;14:13S-21S. https://doi.org/10.1016/0893-133x(95)00200-w
  11. Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 2012;139:116-128. https://doi.org/10.1016/j.schres.2012.05.007
  12. De Hert M, Sermon J, Geerts P, Vansteelandt K, Peuskens J, Detraux J. The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics. CNS Drugs 2015;29:637-658. https://doi.org/10.1007/s40263-015-0269-4
  13. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063-2071. https://doi.org/10.1016/S0140-6736(12)60239-6
  14. Takeuchi H, Kantor N, Sanches M, Fervaha G, Agid O, Remington G. One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. Br J Psychiatry 2017;211:137-143. https://doi.org/10.1192/bjp.bp.116.186007
  15. Hui CLM, Honer WG, Lee EHM, Chang WC, Chan SKW, Chen ESM, et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry 2018;5:432-442. https://doi.org/10.1016/S2215-0366(18)30090-7
  16. Sampson S, Mansour M, Maayan N, Soares-Weiser K, Adams CE. Intermittent drug techniques for schizophrenia. Cochrane Database Syst Rev 2013:CD006196.
  17. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68 Suppl 1:20-27.
  18. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 2009;29:64-73. https://doi.org/10.1592/phco.29.1.64
  19. Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry 2013;13:50. https://doi.org/10.1186/1471-244x-13-50
  20. Shimomura Y, Kikuchi Y, Suzuki T, Uchida H, Mimura M, Takeuchi H. Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms. Schizophr Res 2020;215:8-16. https://doi.org/10.1016/j.schres.2019.09.013
  21. Dans AL, Dans LF, Guyatt GH, Richardson S. Users' guides to the medical literature: XIV. how to decide on the applicability of clinical trial results to your patient. JAMA 1998;279:545-549. https://doi.org/10.1001/jama.279.7.545
  22. Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea health insurance review and assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 2017;32:718-728. https://doi.org/10.3346/jkms.2017.32.5.718
  23. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010;167:686-693. https://doi.org/10.1176/appi.ajp.2009.09060802
  24. Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry. 11th ed. Philadelphia: Wolters Kluwer;2015.
  25. Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia: a review of the past decade. Eur Psychiatry 2012;27:9-18. https://doi.org/10.1016/j.eurpsy.2011.02.005
  26. Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 2014;5:43-62. https://doi.org/10.2147/PROM.S42735
  27. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223. https://doi.org/10.1056/NEJMoa051688
  28. Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry 2018;175:765-773. https://doi.org/10.1176/appi.ajp.2018.17091001
  29. Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry 2016;209:361-365. https://doi.org/10.1192/bjp.bp.116.182683
  30. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651. https://doi.org/10.1093/schbul/23.4.637